Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
anti-diabetic drugs · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LixiLan | EXPERIMENTAL | LixiLan (insulin glargine/lixisenatide) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted. Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period. |
| insulin glargine | ACTIVE_COMPARATOR | Insulin glargine (HOE901) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted. Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period. |
| Name | Type | Description |
|---|---|---|
| Insulin glargine/lixisenatide (HOE901/AVE0010) | DRUG | Pharmaceutical form: solution Route of administration: subcutaneous |
| Insulin glargine (HOE901) | DRUG | Pharmaceutical form: solution Route of administration: subcutaneous |
| Oral anti-diabetic drugs | DRUG | Pharmaceutical form: tablet Route of administration: oral |
Inclusion criteria : * Patient with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year before the screening visit, receiving 1 or 2 OADs that can be Biguanide,Thiazolidinedione (TZD), -Alpha-glucosidase-inhibitor (alpha-GI),Sodium glucose co-transporter 2 (SGLT2) inhibitor,Sulfonylurea (...
Anti-diabetic drugs are used for the treatment of Type 2 Diabetes Mellitus. The drug is being developed by Sanofi and is currently in Phase 3 clinical development. It is a small molecule therapeutic intended to help manage blood glucose levels in patients with this condition.
Anti-diabetic drugs target pathways involved in glucose regulation, specifically through the combination of insulin glargine and lixisenatide. This fixed ratio combination aims to improve glycemic control in patients with Type 2 Diabetes Mellitus by addressing both basal insulin and postprandial glucose excursions.
Anti-diabetic drugs is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of this drug for the treatment of Type 2 Diabetes Mellitus.
Anti-diabetic drugs is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug is being evaluated for its efficacy and safety in patients with Type 2 Diabetes Mellitus.
Anti-diabetic drugs has been studied in a Phase 3 clinical trial with the identifier NCT02752828. This trial, titled 'Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan,' enrolled 521 participants and has been completed.
Anti-diabetic drugs is also known as LixiLan, which is the insulin glargine/lixisenatide fixed ratio combination. This combination is being developed by Sanofi for the treatment of Type 2 Diabetes Mellitus. The Phase 3 trial NCT02752828 evaluated this fixed ratio combination against insulin glargine alone.